RxDoctor Payments Data

Lauren Dubberstein, APRN

Family · Edmond, OKNPI 1689055600

Payments from drug & device makers

$4,449in general payments, 2019–2025

Across 268 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$587
  • Novo Nordisk$531
  • AstraZeneca$433
  • Lilly USA, LLC$388
  • Pfizer$289
  • Sanofi-aventis U.S. LLC$247
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,449 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$37,883
Medicare patients
206
Services billed
997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$21,598
JardianceEmpagliflozin12$18,563
EliquisApixaban16$13,544
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$10,230
MyrbetriqMirabegron16$10,015
JanuviaSitagliptin Phosphate11$9,276
Atorvastatin Calcium125$1,578
Aripiprazole16$867
Levothyroxine Sodium113$859
Omeprazole57$775
Albuterol Sulfate HfaAlbuterol Sulfate24$747
Losartan Potassium54$722
Venlafaxine Hcl ErVenlafaxine Hcl28$696
Tramadol Hcl71$659
Bupropion XlBupropion Hcl25$645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$531$21,59821 claims
Boehringer IngelheimJardiance$228$18,56312 claims
PfizerEliquis$289$13,54416 claims
GSKTrelegy Ellipta$205$10,23018 claims
Astellas Pharma US IncMyrbetriq$61$10,01516 claims
MerckJanuvia$56$9,27611 claims
AbbVieSynthroid$587$56413 claims
Almatica Pharma LLCSertraline Hcl$47$31222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.

Other family in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →